The global cardiac AI monitoring and diagnostics market accounted for USD 1.35 billion in 2023 and is expected to reach USD 16.13 billion by 2034 with a CAGR of 25.27% during the forecast period 2024-2034. The market will grow as a result of factors such as the rising prevalence of cardiovascular disease (CVD), improvements in artificial intelligence and machine learning, wearable device adoption, telemedicine and remote patient monitoring, government initiatives and funding, and an increasing emphasis on preventive healthcare.
The capabilities of cardiac monitoring and diagnostic systems have been greatly improved by the quick developments in artificial intelligence and machine learning technology. Large-scale cardiac data can be analyzed by AI algorithms with great accuracy and efficiency, allowing for customized treatment regimens, early abnormality diagnosis, and predictive analytics for improved patient outcomes. For instance, HeartFlow said in December 2023 that a study showcasing the clinical usefulness of its non-invasive coronary artery disease (CAD) assessment technology has been published. The study emphasizes how well HeartFlow's AI-based strategy guides CAD patients' treatment selections.
By product, the software segment accounted for the highest revenue-grossing segment in the global cardiac AI monitoring and diagnostics market in 2023 and is predicted to grow at the fastest CAGR during the forecast period owing to the increasing demand for AI-powered analytics, integration with existing healthcare systems, and the shift towards preventive healthcare strategies. For instance, Biofourmis announced in February 2024 that it was acquiring PhysioWave, a digital therapeutics business that specialized in heart care. The portfolio of Biofourmis in cardiac health management is strengthened by this acquisition.
By type, the cardiac diagnostics segment accounted for the highest revenue-grossing segment in the global cardiac AI monitoring and diagnostics market in 2023 owing to the growing prevalence of cardiovascular diseases, advancements in diagnostic technologies, and rising adoption of AI-powered cardiac imaging and testing solutions. For instance, Cardiologs announced in November 2023 that it has received FDA authorization to expand the usage of its cloud-based cardiac monitoring software to pediatrics. The use of Cardiologs' AI technology in pediatric cardiology has expanded with this extension. Additionally, the cardiac monitoring segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing demand for continuous remote monitoring, proliferation of wearable devices, and integration of AI algorithms for real-time analysis of cardiac data.
By application, the ischemic heart disease segment accounted for the highest revenue-grossing segment in the global cardiac AI monitoring and diagnostics market in 2023 owing to the growing prevalence of ischemic heart disease, advancements in diagnostic imaging technologies, and increasing adoption of AI-powered solutions for early detection and management. For instance, Caption Health's AI-guided ultrasound software was approved by the FDA in January 2024, allowing physicians to perform echocardiograms without the need for specific training. This approval is a major step in increasing the availability of cardiac diagnostics. Additionally, the cardiac arrhythmias segment is predicted to grow at the fastest CAGR during the forecast period owing to the expansion of remote monitoring capabilities, rising incidence of arrhythmias, and integration of AI algorithms for accurate detection and personalized treatment recommendations.
By end-user, the hospitals segment accounted for the highest revenue-grossing segment in the global cardiac AI monitoring and diagnostics market in 2023 owing to the increased adoption of advanced cardiac monitoring technologies, higher patient footfall, and the need for real-time diagnostic capabilities in hospital settings. For instance, iRhythm Technologies and Verily, Alphabet's biological sciences division, announced a collaboration in March 2024 to create AI-driven solutions for remote heart monitoring. The partnership seeks to improve arrhythmia detection efficiency and accuracy. Additionally, the diagnostic centers segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising demand for specialized cardiac diagnostic services, expanding healthcare infrastructure, and increasing focus on early detection and management of cardiovascular diseases.
North American region is anticipated to have the highest revenue share during the forecast period owing to the high prevalence of cardiovascular diseases, strong healthcare infrastructure, and extensive adoption of advanced cardiac monitoring and diagnostic technologies. Additionally, the Asia Pacific region is estimated to grow at the fastest CAGR during the forecast period owing to the increasing awareness about cardiac health, rising healthcare expenditure, and rapid adoption of advanced medical technologies in emerging economies within the region. For instance, Volta Medical's AI-enabled atrial fibrillation software solution, Volta AF-Xplorer, was cleared by the FDA in May 2023.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
The capabilities of cardiac monitoring and diagnostic systems have been greatly improved by the quick developments in artificial intelligence and machine learning technology. Large-scale cardiac data can be analyzed by AI algorithms with great accuracy and efficiency, allowing for customized treatment regimens, early abnormality diagnosis, and predictive analytics for improved patient outcomes. For instance, HeartFlow said in December 2023 that a study showcasing the clinical usefulness of its non-invasive coronary artery disease (CAD) assessment technology has been published. The study emphasizes how well HeartFlow's AI-based strategy guides CAD patients' treatment selections.
By product, the software segment accounted for the highest revenue-grossing segment in the global cardiac AI monitoring and diagnostics market in 2023 and is predicted to grow at the fastest CAGR during the forecast period owing to the increasing demand for AI-powered analytics, integration with existing healthcare systems, and the shift towards preventive healthcare strategies. For instance, Biofourmis announced in February 2024 that it was acquiring PhysioWave, a digital therapeutics business that specialized in heart care. The portfolio of Biofourmis in cardiac health management is strengthened by this acquisition.
By type, the cardiac diagnostics segment accounted for the highest revenue-grossing segment in the global cardiac AI monitoring and diagnostics market in 2023 owing to the growing prevalence of cardiovascular diseases, advancements in diagnostic technologies, and rising adoption of AI-powered cardiac imaging and testing solutions. For instance, Cardiologs announced in November 2023 that it has received FDA authorization to expand the usage of its cloud-based cardiac monitoring software to pediatrics. The use of Cardiologs' AI technology in pediatric cardiology has expanded with this extension. Additionally, the cardiac monitoring segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing demand for continuous remote monitoring, proliferation of wearable devices, and integration of AI algorithms for real-time analysis of cardiac data.
By application, the ischemic heart disease segment accounted for the highest revenue-grossing segment in the global cardiac AI monitoring and diagnostics market in 2023 owing to the growing prevalence of ischemic heart disease, advancements in diagnostic imaging technologies, and increasing adoption of AI-powered solutions for early detection and management. For instance, Caption Health's AI-guided ultrasound software was approved by the FDA in January 2024, allowing physicians to perform echocardiograms without the need for specific training. This approval is a major step in increasing the availability of cardiac diagnostics. Additionally, the cardiac arrhythmias segment is predicted to grow at the fastest CAGR during the forecast period owing to the expansion of remote monitoring capabilities, rising incidence of arrhythmias, and integration of AI algorithms for accurate detection and personalized treatment recommendations.
By end-user, the hospitals segment accounted for the highest revenue-grossing segment in the global cardiac AI monitoring and diagnostics market in 2023 owing to the increased adoption of advanced cardiac monitoring technologies, higher patient footfall, and the need for real-time diagnostic capabilities in hospital settings. For instance, iRhythm Technologies and Verily, Alphabet's biological sciences division, announced a collaboration in March 2024 to create AI-driven solutions for remote heart monitoring. The partnership seeks to improve arrhythmia detection efficiency and accuracy. Additionally, the diagnostic centers segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising demand for specialized cardiac diagnostic services, expanding healthcare infrastructure, and increasing focus on early detection and management of cardiovascular diseases.
North American region is anticipated to have the highest revenue share during the forecast period owing to the high prevalence of cardiovascular diseases, strong healthcare infrastructure, and extensive adoption of advanced cardiac monitoring and diagnostic technologies. Additionally, the Asia Pacific region is estimated to grow at the fastest CAGR during the forecast period owing to the increasing awareness about cardiac health, rising healthcare expenditure, and rapid adoption of advanced medical technologies in emerging economies within the region. For instance, Volta Medical's AI-enabled atrial fibrillation software solution, Volta AF-Xplorer, was cleared by the FDA in May 2023.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Product, Type, Application, and End-User
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
- 20% Free Customization Available to Meet Your Exact Requirement
Segmentation: Cardiac AI Monitoring and Diagnostics Market Report 2023 - 2034
Cardiac AI Monitoring and Diagnostics Market Analysis & Forecast by Product 2023 - 2034 (Revenue USD Bn)
- Software
- Hardware
Cardiac AI Monitoring and Diagnostics Market Analysis & Forecast by Type 2023 - 2034 (Revenue USD Bn)
- Cardiac Diagnostics
- Cardiac Monitoring
Cardiac AI Monitoring and Diagnostics Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Bn)
- Ischemic Heart Disease/CAD
- Cardiac Arrhythmias
- Ischemic Stroke
- Others
Cardiac AI Monitoring and Diagnostics Market Analysis & Forecast by End-User 2023 - 2034 (Revenue USD Bn)
- Hospitals
- Diagnostic Centers
- Others
Cardiac AI Monitoring and Diagnostics Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Cardiac AI Monitoring and Diagnostics Market: Product Estimates & Trend Analysis
8. Cardiac AI Monitoring and Diagnostics Market: Type Estimates & Trend Analysis
9. Cardiac AI Monitoring and Diagnostics Market: Application Estimates & Trend Analysis
10. Cardiac AI Monitoring and Diagnostics Market: End-user Estimates & Trend Analysis
11. Regional Market Analysis
12. North America Cardiac AI Monitoring and Diagnostics Market
13. Europe Global Cardiac AI Monitoring and Diagnostics Market
14. Asia Pacific Global Cardiac AI Monitoring and Diagnostics Market
15. Latin America Global Cardiac AI Monitoring and Diagnostics Market
16. MEA Global Cardiac AI Monitoring and Diagnostics Market
17. Competitor Analysis
18. Company Profiles
Companies Mentioned
- Biofourmis
- Cardiologs
- Caption Health
- HeartFlow. iRhythm Technologies
- AliveCor
- Cardiac Insight
- Bay Labs
- Cardiologs Technologies
- Cardiomatics
- CardiAI
- Cardiologs SA
- CardiologyAI
- Cardiomatics Inc.
- HeartVista.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | October 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 1.35 Billion |
| Forecasted Market Value ( USD | $ 16.13 Billion |
| Compound Annual Growth Rate | 25.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 14 |
